Objective To study the association of a variety of dermatological manifestations related to vascular abnormalities with antiphospholipid antibodies in patients with suspected primary antiphospholipid syndrome.
Abstract
Objective To study the association of a variety of dermatological manifestations related to vascular abnormalities with antiphospholipid antibodies in patients with suspected primary antiphospholipid syndrome.
Method Case-control study. Consecutive patients referred to the coagulation and haemostasis service of a general hospital for the first determination of antiphospholipid antibodies (lupus anticoagulant and anticardiolipin antibodies) and newly diagnosed disorders (for example, thrombocytopenia, thrombotic disorders, and unexplained repeated abortions) were selected. Patients were examined by two dermatologists according to predefined criteria, and information about general characteristics and relevant dermatological and medical histories were coliected using an ad hoc questionnaire. The study was limited to patients without evidence of systemic lupus erythematosus. A total of35 patients was examined; 13 subjects were positive for lupus anticoagulant or anticardiolipin antibodies, or both (cases), and 22 were negative (controls) .
Results Moderate to severe livedo reticularis and acrocyanosis were significantly associated with antiphospholipid antibodies, with relative risks of 13-1 (95°/0 confidence interval 1.1 to 149-0) and tFisher's exact test, p=0-04. To avoid a potential selection bias-for example, selection of cases (or controls) according to some characteristic they show which is related to the risk factor under evaluationl'-we excluded patients referred by a dermatologist from the study. We also excluded patients with SLE, and even assuming the possibility that the referring doctor might have predicted, to some extent, the serological status of patients, it seems unlikely that the patient was selectively referred to our hospital for the determination of antiphospholipid antibodies because of the presence of a relatively subtle cutaneous manifestation such as that studied here. A final methodological issue of our study regards its 'power'. For disorders with a low prevalence (10% or less) in the control group, our study was designed to detect increases in risk of tenfold or more over the controls, while less dramatic increases in risk could not be detected.
Although the cutaneous disorders examined appear to be a heterogeneous group, they have the common characteristic of all being considered to be related to primary vascular abnormalities, functional or thrombotic. Livedo reticularis is a violet discoloration of the skin with a reticular or cobblestone appearance. It is considered to result from disordered blood flow through subpapillary and dermal blood vessels.'7 18 Mild livedo reticularis-that is, light purple discoloration mostly limited to the legs-is considered to be a normal variant, common in young women, whereas moderate to severe livedo reticularisthat is, livedo with a darker purple discoloration affecting the arms and legs, and sometimes other areas-has been described in many diseases including connective tissue diseases. The association of moderate to severe livedo reticularis and antiphospholipid antibodies has been documented in two previous controlled series of patients with SLE." 12 Superficial thrombophlebitis is a well known manifestation of the antiphospholipid syndrome, as is deep vein thrombosis, and it was not surprising that a history of this disorder was considerably more common in our patients positive for antiphospholipid antibodies. Raynaud's phenomenon is characterised by pallor followed by cyanosis of the hands and sometimes feet precipitated by cold and due to paroxysmal constriction of arterioles.'7 21 It has been described in several disorders including connective tissue, haematological (for example, cold haemoagglutinins), and neurovascular disorders (for example, shoulder girdle compression syndrome). The aetiology of idiopathic cases is still unknown but primary alterations in blood flow, including increased blood viscosity, platelet aggregation, and impaired fibrinolysis, have been considered.2' Systemic sclerosis, a disorder in which Raynaud's phenomenon is prominent, has been described in association with antiphospholipid antibodies. 22 23 Neurofibromatosis type I, malignant melanoma, and widespread angiomata in patients in our study with antiphospholipid antibodies remain unexplained, and even if these might be a chance occurrence, in our opinion they merit further study in view of the rarity of the disorders.24
In conclusion, our study provides quantitative evidence of the association of antiphospholipid antibodies *with several cutaneous manifestations, suggesting that these manifestations might appear early in the development of the antiphospholipid syndrome. The 
